Arch Biopartners Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Arch Biopartners wird voraussichtlich einen Umsatzanstieg von 4.2% pro Jahr verzeichnen. Der Gewinn pro Aktie wird voraussichtlich um 36.7% pro Jahr sinken.

Wichtige Informationen

n/a

Wachstumsrate der Gewinne

-35.3%

EPS-Wachstumsrate

Life Sciences Gewinnwachstum	17.0%
Wachstumsrate der Einnahmen	15.6%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	09 Apr 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Gewinn- und Umsatzwachstumsprognosen

OTCPK:ACHF.F - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CAD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
9/30/2025	2	N/A	N/A	N/A	1
9/30/2024	2	N/A	N/A	N/A	1
3/31/2024	2	-2	0	0	N/A
12/31/2023	2	-2	0	0	N/A
9/30/2023	2	-3	0	0	N/A
6/30/2023	2	-4	2	2	N/A
3/31/2023	2	-3	1	1	N/A
12/31/2022	1	-3	-1	-1	N/A
9/30/2022	1	-1	0	0	N/A
6/30/2022	3	0	0	0	N/A
3/31/2022	5	0	-4	-4	N/A
12/31/2021	4	0	-1	-1	N/A
9/30/2021	4	-1	-3	-3	N/A
6/30/2021	2	-3	-4	-4	N/A
3/31/2021	0	-7	-2	-2	N/A
12/31/2020	0	-6	-2	-2	N/A
9/30/2020	0	-5	-2	-2	N/A
6/30/2020	0	-4	-2	-2	N/A
3/31/2020	0	-2	-2	-2	N/A
12/31/2019	0	-2	-2	-2	N/A
9/30/2019	0	-2	-2	-2	N/A
6/30/2019	0	-2	-2	-2	N/A
3/31/2019	N/A	-3	-2	-2	N/A
12/31/2018	N/A	-3	-2	-2	N/A
9/30/2018	N/A	-3	-2	-2	N/A
6/30/2018	N/A	-3	-2	-2	N/A
3/31/2018	N/A	-2	-1	-1	N/A
12/31/2017	N/A	-2	N/A	-1	N/A
9/30/2017	N/A	-2	N/A	-1	N/A
6/30/2017	N/A	-2	N/A	-1	N/A
3/31/2017	N/A	-1	N/A	-1	N/A
12/31/2016	N/A	-1	N/A	-1	N/A
9/30/2016	N/A	-1	N/A	-1	N/A
6/30/2016	0	-1	N/A	-1	N/A
3/31/2016	0	-1	N/A	-1	N/A
12/31/2015	0	-1	N/A	-1	N/A
9/30/2015	0	-1	N/A	0	N/A
6/30/2015	0	-1	N/A	-1	N/A
3/31/2015	0	-1	N/A	0	N/A
12/31/2014	0	-1	N/A	0	N/A
9/30/2014	0	0	N/A	0	N/A
6/30/2014	0	0	N/A	0	N/A
3/31/2014	0	0	N/A	0	N/A
12/31/2013	0	0	N/A	0	N/A
9/30/2013	0	0	N/A	0	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: Unzureichende Daten, um festzustellen, ob das prognostizierte Gewinnwachstum von ACHF.F über der Sparquote liegt (2.4%).

Ertrag vs. Markt: Unzureichende Daten, um festzustellen, ob die Gewinne von ACHF.F schneller wachsen werden als der Markt US

Hohe Wachstumserträge: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von ACHF.F in den nächsten 3 Jahren signifikant steigen werden.

Einnahmen vs. Markt: ACHF.FDie Einnahmen des Unternehmens (15.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.4% pro Jahr).

Hohe Wachstumseinnahmen: ACHF.FDie Einnahmen des Unternehmens (4.2% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ACHF.F in 3 Jahren voraussichtlich hoch sein wird

Arch Biopartners Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Arch Biopartners Inc. Announces St. Michael's Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Anesthesia Clinical Trials Unit Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated-Acute Kidney Injury

Arch Biopartners Clinical Team Publishes Data from Phase II Trial for Lsalt Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with Sars-Cov-2

University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Arch Biopartners Inc. Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated-Acute Kidney Injury

Arch Biopartners Receives Permission from U.S. FDA to Proceed with Phase II Acute Kidney Injury Trial

Arch Biopartners Inc., Annual General Meeting, Apr 02, 2024

Arch Biopartners Inc. Receives Health Canada Approval to Conduct Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Arch Biopartners Inc. Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Arch Biopartners Submits Application to Health Canada to Conduct the Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Arch Biopartners Inc Submits Application to the Turkish Ministry of Health to Conduct a Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Arch Biopartners Inc., Annual General Meeting, Mar 30, 2023

Arch Biopartners Inc Appoints David Luke as Strategic Advisor for the Clinical Trial Development of the Company's Drug Candidate

Canadian Treatments for COVID-19 (CATCO) Trial Receives Approval from Health Canada to Amend Protocol to include LSALT Peptide (Metablok)

Arch Biopartners' Lead Drug Lsalt Peptide to Enter the Canadian Treatments for Covid-19 (Catco) Trial

Arch Biopartners Inc. Provides Update on Phase II Trial for LSALT Peptide

Arch Biopartners Inc. Files New Patent Application for Novel Antibody Candidates Targeting DPEP-1 Mediated Organ Inflammation

Arch Biopartners Inc. Completes Enrollment in Phase II Trial of Metablok (LSALT Peptide) in Hospitalized Patients with COVID-19

Arch Biopartners Receives Health Canada Authorization to Amend Phase II Trial Protocol for LSALT Peptide

Arch Biopartners Inc. Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients

Arch Biopartners Inc. Receives Ethics Committee Approval in Turkey to Dose Additional Patients in the Phase Ii Trial for Lsalt Peptide

University of Calgary Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients with Arch Biopartners Inc

Arch Biopartners Inc. announced that it has received CAD 0.645 million in funding

Arch Biopartners Inc. announced that it expects to receive CAD 0.645 million in funding

Arch Biopartners Inc, Announces Dosing of First Patient in Turkey in Phase II Trial of LSALT peptide to Treat Complications from Covid-19

Arch Biopartners Inc. Announces First Patient Dose in Phase II Trial to Treat Complications in COVID-19

Arch Biopartners Inc. Receives Approval from Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken